1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; p. S819
Main Authors: Felip, E., Krebs, M.G., Carcereny, E., Smeland, K.B., Arriola, E., Llacer Perez, C., Thompson, J., Paz-Ares, L., Domine Gomez, M., Olivares, J.R., Vinolas Segarra, N., García-Campelo, M.R., Ortega Granados, A.L.O., Chisamore, M., Micklem, D., McCracken, N., Rayford, A., Oliva, C., Gorcea-Carson, C., Spicer, J.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.2471